Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?

Abobaker, Anis

Abobaker, Anis.

Abobaker A; Spire Fylde Coast Hospital, St Walburgas road, Blackpool, FY3 8BP, UK. anis.abobaker@yahoo.com.

Eur J Clin Pharmacol ; 76(11): 1619-1620, 2020 Nov.

Article in English | MEDLINE | ID: covidwho-618175

Subject(s)

Anti-Inflammatory Agents/therapeutic use; Coronavirus Infections/drug therapy; Deferoxamine/therapeutic use; Immunologic Factors/therapeutic use; Iron Chelating Agents/therapeutic use; Pneumonia, Viral/drug therapy; Animals; Anti-Inflammatory Agents/pharmacology; Antibodies, Neutralizing/blood; Antiviral Agents/pharmacology; B-Lymphocytes/drug effects; B-Lymphocytes/immunology; Betacoronavirus; COVID-19; Deferoxamine/pharmacology; Enterovirus Infections/blood; Enterovirus Infections/drug therapy; Enterovirus Infections/immunology; HIV-1/drug effects; HIV-1/physiology; Humans; Immunologic Factors/pharmacology; Interleukin-6/immunology; Iron Chelating Agents/pharmacology; Iron Overload/drug therapy; Mice; Pandemics; SARS-CoV-2; Treatment Outcome; Virus Replication/drug effects

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Iron Chelating Agents / Coronavirus Infections / Deferoxamine / Immunologic Factors / Anti-Inflammatory Agents Type of study: Prognostic study Limits: Animals / Humans Language: English Journal: Eur J Clin Pharmacol Year: 2020 Document Type: Article Affiliation country: S00228-020-02942-9

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google